LXN Gluco-Protein test launch planned :
This article was originally published in Clinica
LXN is to launch its Gluco-Protein test in the US by the end of the year. The test, which the company claims is the first self-test for glycated protein (fructosamine), has been granted CLIA-waived status, which means that healthcare providers do not have to send samples for laboratory testing. Gluco-Protein, recently approved for over-the-counter sale by the FDA, will eventually be sold OTC as part of a monitoring device that also offers a rapid test for blood glucose. The two-test device, Duet Glucose Control Monitor, is pending FDA clearance.
You may also be interested in...
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.
Theradaptive's “paint-like” regenerative therapeutic can be applied to any device to promote bone regrowth or regenerate tissue.